Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DXE53Z
|
|||
| Drug Name |
LY3556050
|
|||
| Synonyms |
SCHEMBL16252692; BDBM311911; US10166214, Example 47; AT36106; LY3556050; EN300-1700347; Z3071648657; (1R,5S,6R)-N-{2-methyl-1-[(3-methylpyridin-2-yl)oxy]propan-2-yl}-3-azabicyclo[3.1.0]hexane-6-carboxamide; 1638588-92-7
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Chronic low-back pain [ICD-11: MG30] | Phase 2 | [1] | |
| Company |
Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H23N3O2
|
|||
| Canonical SMILES |
CC1=C(N=CC=C1)OCC(C)(C)NC(=O)C2C3C2CNC3
|
|||
| InChI |
InChI=1S/C16H23N3O2/c1-10-5-4-6-18-15(10)21-9-16(2,3)19-14(20)13-11-7-17-8-12(11)13/h4-6,11-13,17H,7-9H2,1-3H3,(H,19,20)/t11-,12+,13?
|
|||
| InChIKey |
PCINBSQTEDBZDB-FUNVUKJBSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatostatin receptor type 4 (SSTR4) | Target Info | Agonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04874636) Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.